-
GSH and GSSG Assay Kit for Tumor Redox Studies
2026-09-23
Translate hypoxia and immunometabolism into measurable redox endpoints by pairing total glutathione with selective GSSG analysis. This workflow supports reduced glutathione detection in tumor cells, immune-cell models, tissues, plasma, and red blood cells while preserving practical troubleshooting guidance.
-
JAK Inhibitors and Endothelial Cardiovascular Effects
2026-09-22
This study compared six JAK inhibitors in cytokine-stimulated human endothelial cells and showed that suppressing IL-6 does not necessarily normalize adhesion, coagulation, or endothelial survival responses. The findings support concentration-aware interpretation of JAK inhibitor experiments and caution against treating anti-inflammatory activity as a complete surrogate for vascular protection.
-
Liproxstatin-1: A Ferroptosis Assay Compass
2026-09-22
Liproxstatin-1 is a ferroptosis inhibitor that helps distinguish lipid-peroxidation-driven death from downstream membrane failure. This guide uses recent TMEM16F research to show how B4987 can sharpen assay design, controls, and interpretation.
-
Sulfisomidine: A Dual-Pathway Assay Strategy
2026-09-21
Sulfisomidine, also known as sulfamethin, is more than a legacy antibacterial reagent. Its competitive interference with bacterial PABA utilization and mixed-type inhibition of human serum paraoxonase 1 create a practical bridge between microbial folate biology, enzyme kinetics, oxidative stress regulation research, and translational assay design.
-
XAV-939: From Wnt Mechanism to Translational Strategy
2026-09-21
XAV-939 connects tankyrase biology with practical translational decisions across cancer, fibrosis, synovial inflammation, and bone biology. This thought-leadership guide interprets the mechanistic evidence, positions the compound against common pathway-validation approaches, and outlines a disciplined workflow for moving from β-catenin modulation to disease-relevant endpoints.
-
PR-619: Practical Guide to DUB Inhibition
2026-09-20
PR-619 is a reversible, cell-permeable deubiquitylating enzymes inhibitor for mapping ubiquitinated-protein dynamics without directly blocking proteasomal catalytic activity. This guide connects dose planning, autophagy and cancer assays, neurodegeneration models, troubleshooting, and a recent HPV-positive cancer study to practical experimental workflows.
-
Masitinib (AB1010) Practical Protocol Guide
2026-09-19
This guide explains how to use Masitinib (AB1010), SKU A2942, in DMSO-based workflows examining KIT, PDGFRα, PDGFRβ, mast-cell responses, and selected KIT-mutant models. It is not intended for aqueous or ethanol-based protocols, broad-spectrum kinase screening, or clinical treatment decisions without independent evidence.
-
Carvedilol: Applied β-Adrenergic Research Workflows
2026-09-18
Carvedilol combines nonselective β-adrenergic blockade with α1-adrenergic antagonism and measurable antioxidant activity, making it useful across receptor-signaling, vascular, oxidative-stress, and hematopoietic assays. This practical guide connects concentration selection, vehicle control, transplant-model design, and troubleshooting to findings from recent regeneration research.
-
Tropifexor and the Gut–Liver Translation Gap
2026-09-18
Tropifexor (LJN452) gives translational researchers a highly potent, research-grade tool for testing how FXR activation shapes intestinal barrier biology and metabolic signaling. By placing FXR experiments alongside new evidence on triacetin digestion and hepatic AMPK responses, this article outlines a more rigorous strategy for connecting epithelial, hepatic, and nutrient-derived signals without overstating causality.
-
Gastric Cancer Assembloids Model Tumor–Stroma Biology
2026-09-17
The reference study develops patient-derived gastric cancer assembloids by combining matched tumor organoids with autologous stromal cell subpopulations. Its results show that stromal composition alters gene expression and drug sensitivity, providing a more physiologically informative platform for resistance studies and personalized treatment evaluation.
-
One-step TUNEL Cy3 Kit for Apoptosis
2026-09-17
The One-step TUNEL Cy3 Apoptosis Detection Kit uses terminal deoxynucleotidyl transferase (TdT) labeling to visualize apoptotic DNA fragmentation in cells and tissue sections. Its Cy3 signal supports fluorescence microscopy and flow cytometry, while DNase I and camptothecin controls provide practical assay benchmarks.
-
D-Luciferin Potassium Salt for Cancer BLI
2026-09-16
D-Luciferin potassium salt enables repeatable firefly-luciferase readouts across tumor cell tracking, reporter assays, and ATP-linked workflows. Its water solubility supports practical in vivo bioluminescence imaging while offering a clean route to connect longitudinal tumor burden with mechanistic studies such as LNP-delivered miRNA research.
-
RHEB Neddylation, mTORC1, and Liver Tumorigenesis
2026-09-16
The reference study identifies RHEB as a non-cullin substrate of the UBE2F–SAG neddylation machinery and shows that modification at K169 strengthens RHEB lysosomal localization and GTP binding. Genetic evidence links this axis to mTORC1 activity, liver steatosis, PTEN-loss-driven tumorigenesis, and survival-associated features of hepatocellular carcinoma.
-
3X FLAG Peptide Workflow Guide
2026-09-15
Build more reliable FLAG-tagged protein workflows with a small, hydrophilic 3X epitope designed for purification, detection, and structural biology. This guide combines practical protocol starting points with metal-aware assay controls and lessons from recent GM130 condensate research.
-
GSH and GSSG Assay Kit: Redox Decisions in Hypoxia
2026-09-15
Explore how the GSH and GSSG Assay Kit supports reduced glutathione detection and mechanistically informed redox analysis in hypoxic tumor biology. This guide connects glutathione measurements with sample handling, immunometabolism, and interpretation beyond a simple GSH/GSSG ratio.